
The temptation to use uncontrolled, early, small studies to support further development of products may prove problematic for emerging biopharma companies.
The temptation to use uncontrolled, early, small studies to support further development of products may prove problematic for emerging biopharma companies.
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Significant differences exist in the characteristics of the priority review drugs approved by the FDA and the European Medicines Agency.
Published: February 13th 2025 | Updated: March 4th 2025
Published: February 19th 2025 | Updated: February 26th 2025
Published: March 24th 2023 | Updated:
Published: April 28th 2021 | Updated:
Published: July 26th 2024 | Updated:
Published: January 31st 2024 | Updated: